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1. Introduction 
Diabetes mellitus a chronic slow progressing catastrophe and is a major medical problem 
throughout the world. Diabetes causes an array of long-term systemic complications that 
have considerable impact on patient as well as society, as the disease typically affects 
individuals in their most productive years (Federman et al., 1994; Bhavsar et al., 2010). In 
addition, this increase appears to be greater among certain ethnic groups and in developing 
countries. Diabetic retinopathy is one of the main causes of diabetic complications. It causes 
visual impairment and finally blindness, a result of long-term accumulated damage to the 
small blood vessels in the retina. The proportion of blindness due to diabetic retinopathy 
ranges from close to 0% in most of Africa, to 3–7% in much of South-East Asia and the 
Western Pacific, to 15–17% in the wealthier regions of the Americas, Europe and the 
Western Pacific (Resnikoff et al. 2004; Zhang et al., 2010). According to the WHO fact sheet 
Aug. 2011, 346 million people worldwide have diabetes (World Health Organization 
[WHO], 2011). About 50% of persons with diabetes are unaware that they have the 
condition, although about 2 million deaths every year are attributable to complications of 
diabetes. After 15 years, about 2% of persons with diabetes become blind, and about 10% 
develop severe visual loss (WHO 2011). After 20 years, more than 75% of patients will have 
some form of diabetic retinopathy (Barcelo et al., 2003). 
Post onset diabetes with increasing age, there is a higher risk of developing diabetic 
retinopathy and its complications, including diabetic macular oedema or proliferative 
diabetic retinopathy increases. The exact mechanism by which diabetes causes retinopathy 
remains unclear, but several theories have been postulated to explain the typical course and 







history of the disease (Crawford et al. 2009). Chronic hyperglycemia exerts protein gluco-
oxidation, a process involving the non-enzymatic modification of tissue proteins by 
physiologic sugars in vivo, appears to play a central role in the pathogenesis of diabetic 
complications. One mechanism linking uncontrolled hyperglycaemia with tissue damage such 
as that in diabetic retinopathy is the formation and accumulation of advanced glycation end-
products (AGE) (Hammes et al, 1996). Ex vivo and in vivo studies have indicated that AGE 
induce irreversible cross-links in long-living extracellular matrix (Brownlee et al., 1988; Fu et 
al., 1992; Sell et al., 1992; Sell et al., 1993) and, upon binding to specific cellular proteins, change 
the local concentrations of cytokines, growth factors and other bioactive molecules  (Schleicher 
& Nerlich 1996; Vlassara et al, 1985). Accumulation of AGEs depends on both sugar 
concentration and the rate of protein turnover. Thus, some proteins that reach critical levels of 
AGE modification in sites where diabetic complications occur may turnover too quickly for 
normal levels of blood glucose to cause functional alterations, while proteins with a longer 
half-life would continue to be modified over a longer period of time (Brownlee 1995). 
The relation between diabetes mellitus and oxidative stress is well known. With the onset of 
diabetes, persistent and chronic hyperglycemias causes increased production of free radicals 
through auto-oxidation of glucose, via nonenzymatic protein glycation and enhanced flux of 
glucose through the polyol pathway (Giugliano et al., 1996). The generation of reactive 
oxygen species and protein glycation are strictly interconnected (Palm et al, 2003). Levels of 
serum AGE are increased in diabetes mellitus before they have developed microvascular 
complications (Berg et al., 1997). These increased serum levels of AGE can predict changes 
in microvascular morphology in patients with diabetic retinopathy. Proteins containing 
AGE are highly immunogenic (Reddy et al., 1995) and anti-AGE antibodies were found in 
the sera of patients with diabetes (Shibayama et al, 1999; Baydanoff et al., 1996). Our 
research team has hypothesized that increase in the titre of anti-AGE antibodies has a direct 
role in the pathogenesis of diabetes microvascular complications especially diabetic 
retinopathy. Detection and characterization of antibodies against gluco-oxidative modified 
proteins could help in understanding the exact aetiology of gluco-oxidation of protein and 
diabetic retinopathy. Anti-gluco-oxidative modified proteins antibodies may potentially 
help in the prediction and /or prognosis of diabetes retinopathy. However the exact 
pathophysiology is yet to be ascertained. 
2. Glycation 
Reducing sugars such as glucose (or other reducing sugars as fructose, pentoses, galactose, 
mannose, ascorbate, xylulose) reacts nonenzymatically with free ε-amino groups in protein, 
lipids and nucleic acids through a series of reactions forming Schiff’s bases and Amadori 
products to produce AGEs; and this process, also known as the Milliard reactions. In theory, 
every protein can be modified by glycation. Indeed, many protein-AGE adducts have been 
identified, e.g. glycated fibrinogen, collagen, albumin, herpes simplex glycoprotein B, 
hemoglobin, ǃ2-microglobulin, and low density lipoprotein (Raj et al., 2000; Cribbs et al., 
2000). Albumin is the most abundant protein in human serum, about 35-50 g/liter, and it is 
prone to glycation (Carter & Ho 1994). Non-enzymatic glycation of albumin occurs at 
multiple sites; glucose can attach to Lys199, Lys281, Lys439, and Lys525 as well as some 
other lysine and arginine residues and also at the N-terminal residues of polypeptides (Iberg 
& Fluckiger 1986). In fact, only a small number of factors are known to result in the variation 
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of serum albumin. The alteration in the structure of albumin due to uncontrolled 
hyperglycemia causes vascular complications (Bourdon et al., 1999). 
Glycation is a classical covalent reaction in which, by means of N-glycoside bonding, the 
sugar-protein complex is formed through a series of chemical reactions described for the 
first time by a chemist Louis Camille Maillard in 1912 (Sing et al., 2001). Maillard reactions 
are complex, multilayered, and can be analyzed in three steps. (i) The sugar-protein complex 
is formed first (Amadori rearrangement), an early product of non-enzymatic glycation 
leading to intermediary products which are precursors of all later compounds. (ii) 
Formation of numerous intermediary products, some of which are very reactive and 
continue the glycation reaction. (iii) Final phase consists of polymerization reaction of the 
complex products formed in the second step, whereby heterogeneous structures named 
advanced glycation end products (AGE) are formed (Fig. 1). 
 
Fig. 1. Schematic presentation of potential pathway leading to AGE formation. The 
abbreviations given above are represented as, GLO=glyoxal; MG=methylglyoxal; 3-DG=3-
deoxyglucosone; CML=carboxymethyl-lysine (Turk, 2001). 
AGE constitute a heterogenous group of molecules (Peppa & Vlassara 2005) and its 
formation takes place continuously within the body during ageing, however it is extremely 
accelerated in diabetes (Vlassara & Palace 2002; Fu et al., 1996; Thorpe & Baynes 1996; Peppa 
et al., 2004). Some of the major AGEs are carboxymethyl lysine (CML) and pentosidine and 
also include many reactive intermediates or AGE-precursors such as 1- or 3-
deoxyglucosone, methylglyoxal (MG) and their derivatives. AGE can cause tissue damage 
by two main pathways: they either form cross-links that disrupts the structure and function 






surface receptors inducing deleterious consequences, leading to altered intracellular events 
that induce oxidative stress and inflammation (Vlassara & Palace 2002; Peppa et al., 2002; 
Peppa et al., 2004; Vlassara 2001). AGE induced pathogenesis of diabetic retinopathy occurs 
via alteration of small vessel wall integrity and structure, by inducing cytokines, growth 
factors and increased oxidative stress (Sheetz & King 2002; Vlassara & Palace 2002; Peppa et 
al., 2002; Peppa et al., 2004; Vlassara 2001; Stitt et al., 1997; Stitt 2001; Yamagishi et al., 2002). 
Ex vivo, retinal endothelial cells exposed to AGE overproduce vascular endothelial growth 
factor (VEGF) through oxidative stress induction, protein kinase-C pathway activation and 
abnormal endothelial nitric oxide synthase (eNOS) expression (Mamputu & Renier 2002; 
Chakravarthy et al., 1998). Retinal organ cultures show an increased glyoxal induced CML 
formation in association with increased apoptosis and cell death, restored by anti-AGE 
agents and antioxidants (Mamputu & Renier 2002). Increased AGE accumulation was found 
in the retinal pericytes of diabetic rats after 8 months of diabetes (Stitt et al., 1997). In 
addition, exogenous AGE-albumin administration in non-diabetic animals accumulated 
around and within the pericytes, colocalized with AGE receptors inducing retinal vessel 
wall thickening and loss of retinal pericytes (Xu et al., 2003; Clements et al., 1998). In 
humans, it has been found that with the increasing severity of retinopathy there is a 
proportional increase in AGE accumulation around retinal blood vessels (koya et al., 
2002). Glycation of vitreous collagen was also observed in human donor eyeballs 
(Sulochana et al, 2003). In addition, studies using anti-AGE agents further support the role 
of AGE in diabetic retinopathy (Yamagishi et al., 2002; Chappey etal., 1997; Reber et al., 
2003). AGE have also been linked to the changes associated with diabetic keratopathy 
through their effect in reducing corneal epithelial cell adhesion (Matsumoto et al., 1997). 
Furthermore, glycation of the vitreal collagen fibrils leading to dissociation from 
hyaluronan and resultant destabilization of the gel structure has been associated with 
vitreous liquefaction and posterior vitreous detachment in diabetes (Stevens 1998; Sebag 
et al., 1992; Stitt et al., 1998). 
3. Pathophysiological mechanism of AGEs formation in diabetic retinopathy 
The knowledge of gluco-oxidation of proteins and AGEs has considerably expanded over the 
years, and a large body of evidence has documented their implication in diabetes-related 
complications (Singh et al., 2001; Turk et al., 2001; Brownlee 2001; Monnier et al., 2005; 
Huebschmann et al., 2006). In the process of glycation, AGE peptides that are released as 
degradation products, which partly occur through proteolysis of the matrix component are 
commonly named as glycotoxins. Glycated proteins are toxic for neuronal cells, retinal 
capillary cells, leukocytes, pericytes, and endothelial cells (Takeuchi et al., 2000; Yamagishi et 
al., 2002; Lyons et al., 2000). Toxicity of glycated polypeptides may be due to the AGE 
modification or due to the aggregation state of the polypeptides. Glycotoxins are very reactive 
on entering blood circulation. Non elimination of these proteins through the kidneys leads to 
recirculating AGE peptides which can generate new AGE products that react with other 
plasma or tissue components. At this stage, glycation becomes an autonomic process, which 
significantly accelerates the progress of the complication (Turk 2001). 
Immunoglobins are glycated differently according to their class. The glycation of 
immunoglobulin-M is twofold greater than that of immunoglobulin G, and can be related to 
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the difference in amino acid composition. Albumin can be glycated at multiple sites. In 
diabetic patients, excessive glycation of fibrinogen and fibrin has been reported (Chappey et 
al., 1997). Hemoglobin is glycated at two sites: on the valine residue of the N-terminal ǃ-
chains at the ε-amino group of the ǂ and ǃ-chains, and at the N-termini of the ǂ-chains 
(McDonald et al., 1978). Other intracellular and membrane proteins of red blood cells (RBC) 
are also glycated, for example Spectrin, a major RBC membrane protein, band 3 
transmembrane protein, and band 4-1 (Retnaikes et al., 1987; Bryszewska & Szosland 1988). 
Hence glycation results in RBC deformability and an increased adherence to endothelium. 
Membrane proteins of platelets can also be glycated.  Increased binding of fibrinogen and 
platelet aggregation observed in diabetic patients can be related to the glycation of 
adenosine diphosfate receptors. Lipids can also contribute to the modifications of platelet 
functions in diabetes (Chappey et al., 1997). Hyperglycemia can also induce protein 
aggregation which is associated with diabetes and its complications. Gluco-oxidation of 
proteins induces refolding of globular proteins, accompanied by the formation of cross ǃ-
structure (Bouma et al., 2003).  
Gluco-oxidation of proteins forms complex and irreversible molecules, which accumulate in 
the retinal vasculature of patients with diabetes and streptozotocin-induced diabetic rats 
(Hammes et al., 1999; Stitt et al., 1997) and have been implicated in the development of 
diabetic retinopathy (Boehm et al., 2004 Genuth et al., 2005). Chronic exposure of the 
endothelium to AGEs has been shown to increase retinal vascular permeability in vivo (Stitt 
et al., 2000) and ex vivo (Leto et al., 2001). AGEs, however, have also been shown to increase 
capillary permeability acutely (Sampietro et al., 1987). Activation of AGE recepter (RAGE) 
and production of oxygen free radicals have been shown to mediate cellular responses to 
AGEs; however, the signalling pathways involved in the early permeability response are 
unknown (Kislinger et al., 1999; Bonnardel-Phu et al., 1999). 
It has been suggested that, in diabetes, oxidative stress plays a key role in the pathogenesis of 
vascular complications, both microvascular and macrovascular, and an early marker of such 
damage is the development of an endothelial dysfunction (Giugliano et al., 1996; Cai & 
Harrison 2000). Evidence implicates hyperglycemia-derived oxygen free radicals as mediators 
of diabetic complications. Recently recognized relationship between ǂ-oxoaldehydes and 
biologically important macromolecules highlights the intermediate step of advanced glycation 
cascade (Beisswenger et al., 2003a; Beisswenger et al., 2003b; Thornalley 2005). Diabetic 
individuals may exhibit elevated levels of iron and free copper ions (Cutler 1978; Mateo et al., 
1978), which in the presence of glycated proteins ex vitro have been shown to generate free 
radicals (Hunt 1994). The accumulation of glycated material in tissues that contain free copper 
ion contribute to the generation of free radical mediated damage. These highly reactive species 
are capable of causing oxidative degradation of protein ex vivo (Hunt 1994). The formation of 
ǂ-dicarbonyl compounds is known to be an essential step for the cross-linking of proteins and 
subsequent free radical generation (Rahbar & Figarola 2003). Methylglyoxal is increased 5-6 
fold; in adult onset, non-insulin dependent diabetes mellitus as compared to healthy 
individuals. In the presence of oxidative stress, glycation of proteins by methylglyoxal is 
enhanced. This may underlie the link of glycation and oxidative stress with diabetic 
complications, and may also contribute to pathological processes of ageing.   
Structural and functional modification of host-protein is a common feature of all AGEs 






of extracellular matrix, intracellular signal transduction and protein function, AGEs may 
contribute to the pathogenesis of diabetic retinopathy (Poukupec et al., 2003). A mechanism 
by which AGE-modified proteins may exert their effect is binding to RAGE identified on a 
variety of cells including endothelial and smooth muscle cells, and by internalization and 
degradation via monocyte/macrophage AGE-receptors. Using radiolabeled AGE proteins it 
has been shown that several cells, such as human and mouse monocyte, macro-phage and 
lymphocyte, bind these types of glycated compounds in a relatively selective way (Gilcrease 
& Hoover 1990; Imani et al., 1993). Gluco-oxidative modified proteins bind to these cells in a 
saturable manner with a dissociation constant in the range of 50–200 mmol/l-1. The putative 
receptors for AGE have been isolated from cell membranes and purified, and were reported 
to have different molecular weights: 30–50 KD for renal tissue, 36–83 KD for a macrophage 
cell line, 60–90 KD for liver cells (Yang et al., 1991; Skolnik et al., 1991). A carbohydrate-
binding protein of 35 KD named Galectin 3 is present on lymphocytes, macrophages, 
endothelial, mesangial, smooth muscle cells, and fibroblasts, and binds AGE with a higher 
affinity than other carbohydrates (Vlassara et al., 1995). 
Increased hyperglycemia caused protein gluco-oxidation and/or glucose auto-oxidation 
enhanced formation of AGEs, stimulate the expression of RAGE and hence NADPH oxidase 
activation. Activation of NADPH oxidase increased the production of free reactive oxygen 
radicals can up-regulate vascular endothelial growth factor (VEGF) in retinal cells via 
nuclear transcription factors (eg. NF-kappaB) potentially promoting retinal 
neovascularisation and increasing permeability to proteins across the retinal barrier. 
Increased RAGE expression has been found on endothelial cells, vascular smooth muscle 
cells and cardiac myocytes of diabetic patients (Schmidt et al., 1999). It has been reported 
that ligation of AGE with RAGE causes activation of intracellular signaling, gene expression, 
and production of proinflammatory cytokines and free radicals, thus playing an important 
role in the development and progression of diabetic micro- and macroangiopathy (Kim et 
al., 2005). 
4. Oxidative stress and diabetic retinopathy 
Diabetic retinopathy pathogenesis is multifactorial, and the precise mechanisms are unclear. 
Several mechanisms have been proposed, including enhanced free radical production ROS 
(Brownlee et al., 1998; Koya & King 1998).  Oxidative stress is increased in the retina in 
diabetes, and it is considered to play an important role in the development of retinopathy 
(Manikanth et al., 2010; Armstrong et al., 1998). It has been already proved that oxidative stress 
and hyperglycemia are central to chronic pathogenesis of diabetic retinopathy (Turk 2010). 
Increased levels of free radicals have a direct effect on in vivo protein. Oxidative stress induced 
modification of proteins is initiated mainly by reactions with hydroxyl radical; however, the 
course of the oxidation process is determined by the availability of oxygen and superoxide 
radical or its protonated form (HO2˙). Collectively, these ROS can lead to oxidation of amino 
acid residue side chains, cross-linking of soluble and/or membrane-bound proteins, oxidation 
of the protein backbone resulting in protein damage and yielding larger aggregates  
fragmentation. In the meantime, it has been shown that other forms of ROS may yield similar 
products and that transition metal ions can substitute for hydroxyl and superoxide radicals in 
some of the reactions (Berlett & Stadtman 1997). Even peptide bonds are subject to oxidative 
modification by ROS (Adams et al., 1999; Dhalla et al., 2000; Schoonover 2001). 
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Animal studies have demonstrated that oxidative stress contributes not only to the 
development of diabetic retinopathy but also to the resistance of retinopathy to reverse after 
good glycemic control is reinstituted—the metabolic memory phenomenon (Berg et al., 
1997). Various mechanisms have been suggested to contribute to the formation of these 
reactive oxygen-free radicals. Glucose auto-oxidation is one of the major sources of ROS that 
is generated by oxidative pathways of glycation. Glucose exists in equilibrium with its 
enediol, which can undergo auto-oxidation to form an enediol radical. This radical reduces 
molecular oxygen to generate the superoxide radical and becomes oxidized itself to a 
dicarbonyl ketoaldehyde that reacts with protein amino groups forming a ketoamine, Fig. 2 
(Wolff and Dean 1987a). Ketoamine are similar to, although more reactive, than Amadori 
products and participate in AGE formation (Ahmed et al., 2005). The superoxide anion 
radicals undergo dismutation to hydrogen peroxide, which if not degraded by catalase or 
glutathione peroxidase, and in the presence of transition metals, can lead to production of 
extremely reactive hydroxyl radicals (Wolff and Dean 1987; Jiang et al., 1990).  
 
Fig. 2. Role of glucose auto-oxidation in the formation of reactive oxygen species induced 
protein damage (Wolff and Dean 1987a). 
In hyperglycemic conditions, most of the carbonyl compounds generated by glycation need 
oxidative steps in their formation. The protein dicarbonyl compounds can participate in 
AGE formation and are referred to as glyco-oxidative products (Liggins & Furth 1997). 
Studies in diabetic rats showed elevated levels of superoxide in retinal cells with high 
glucose levels (Du et al., 2003; Cui et al., 2006), as well as increased levels of hydrogen 






them from leaking. Prolonged hyperglycemia damages the tight junctions by oxidative 
stress and the vessels become leaky allowing fluid or blood to seep into the retina, thus 
resulting in the swelling of the retina (Harhaj & Antonetti 2004). Recently the etiology 
behind the production of superoxide in endothelial cells in diabetic complications has been 
elucidated (Brownlee 2001).  There are four pathways suggested to be involved in the 
pathogenesis of diabetic complications due to increased production of free radical (increased 
polyol pathway flux, increased advanced glycosylation end product formation, activation of 
protein kinase C, and increased hexosamine pathway flux (Nishikawa et al., 2000; Du et al., 
2002). In diabetes, the activities of antioxidant defense enzymes responsible for scavenging 
free radicals and maintaining redox homeostasis such as SOD, glutathione reductase, 
glutathione peroxidase, and catalase are diminished in the retina (Kowluru et al., 2001; 
Haskins et al., 2003). The intracellular antioxidant GSH is probably the most important 
antioxidant in the cell and acts as an ROS scavenger and modulates intracellular redox state 
(Meister 1988). The levels of this intracellular antioxidant are decreased in the retina in 
diabetes (Kern et al., 1994), and enzymes responsible for its metabolism are compromised 
(Lou 2003). Some nonenzymic antioxidants such as vitamin C, vitamin E, and β-carotene are 
also depressed during hyperglycemia induced oxidative stress (Ford et al., 2003). 
5. Autoantibodies in diabetes complications 
The lack of an immune response to self when responses to environmental antigens are retained 
is due to immunological tolerance. The role of tolerance, or lack of tolerance, is important to 
the understanding of autoimmune diseases and transplantation immunobiology (Mackay 
2000). A loss of natural tolerance (to self) underlies all autoimmune diseases. Many more 
individuals develop autoimmune phenomena than autoimmune disease. Immune-mediated 
(Type I) diabetes results from an organ-specific autoimmune-mediated loss of insulin-secreting 
ǃ cells. This chronic destruction process involves both cellular and hormonal components 
detectable in the peripheral blood, months or even years, before the onset of clinical diabetes 
(Kukreja & Maclaren 1999).  In order to elicit an immune response, a molecule must be 
recognized as non-self by the biological system.  
Proteins containing AGE are highly immunogenic and anti-AGE antibodies have been 
found in the sera of patients with diabetes (Reddy et al., 1995; Shibayama et al, 1999; 
Baydanoff et al., 1996). Several AGE structures have been identified including pyrraline, 
pentosidine (Sell & Monnier 1989), (carboxymethyl)lysine (Ahmed et al., 1986), and 
crosslines (Nakamura et al., 1992). Immunological studies using antibodies specific for these 
compounds have confirmed their presence in vivo (Ienaga et al., 1995). However, it is still 
not known whether one of these compounds contributes, as a major AGE structure, to the 
pathogenesis of these diseases, or whether other structures may involve in this process. 
Immunological approaches have been attempted to determine the major AGE structures 
expressed in vivo. Using AGE-BSA as an antigen, researchers prepared a monoclonal anti-
AGE antibody (6D12) in mice as well as a polyclonal anti-AGE antibody in rabbits (Hoeiuchi 
et al., 1986). Immunoreactivity studies of these antibodies have demonstrated an interesting 
observation: both antibodies react with AGE samples obtained from proteins, peptides, 
lysine derivatives, and monoaminocarboxylic acids, suggesting the presence of a common 
AGE structures in these AGE preparations. Immunologic studies using 6D12 monoclonal 
antibodies have disclosed the presence of AGE in several tissues and their potential 
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involvement in disease processes. Anti-AGE antibodies use as a potential biomarker of AGE 
depositions during diabetes and its associated secondary complications. 
There is increasing evidence of the presence of anti-AGE antibodies in diabetes and its 
complications. The role of these antibodies and specifically which particular anti-AGE 
antibodies are involved in the aetiology of diabetic micro- and macrovascular complications 
is, however, yet to be established. The possibility of effective therapeutic intervention 
stresses the importance of detecting anti-AGE antibodies, and advancements in measuring 
anti-AGE antibodies using reliable methods will help determine the role they have in the 
pathogenesis of many diseases, especially diabetes and its complications. 
Antibodies against AGE structures led to the discovery that only a minor proportion of 
AGE are detectable by autoflourescence and they form to a greater extent in 
intracellularly than extracellularly because several glucose fragmentation products which 
occur during the metabolism of glucose in the cell are more reactive than glucose itself 
(Giardino et al., 1994). It was also found that the non-flourescent CML is the major epitope 
against which AGE-antibodies are directed (Reddy et al., 1996). Some AGE-antibodies 
used so far have not been characterized at all. To circumvent this problem researchers 
applied antibodies directed against the proteins that are abundantly available in blood 
and more exposed to blood glucose levels in diabetes mellitus as representative markers 
for the gluco-oxidative pathway. Anti-HSA antibodies have been observed in diabetes 
(Eilat et al., 1981), a fivefold greater occurrence than in nondiabetic persons (Gregor et al., 
1986). Proteins containing AGEs are highly immunogenic and CML is one of the major 
epitopes recognised by anti-AGE antibodies (Reddy et al., 1995; Ikeda et al., 1996). The 
presence of AGE-antibodies in the serum of streptozotocin-diabetic rats as well as in a 
small number of diabetic patients have been reported (Shibayama et al., 1999) AGE can 
exert their immunogenicity, demonstrate that presence of AGEs-immune complexes 
(AGE-IC) in the diabetic patients that may play a role in the artherogenesis (Turk et al., 
2001). Interactions of AGE autoantibodies with AGEs as a continuously produced antigen 
result in the formation of AGE-ICs that may play role in diabetic complications (Jakus and 
Rietbrock, 2004). The analysis of the frequency distribution profile shows that 14% of the 
diabetic subjects display significant antibody binding to AGE-HSA than the control 
subjects (Vay et al., 2000).  
6. Autoantibodies against gluco-oxidative modified proteins in diabetic 
retinopathy 
The autoantibodies have always been important for clinical interest due to their potential 
role in screening, diagnosis, monitoring treatment of effectiveness and prognosis. Non-
enzymatic glycation of proteins can lead to the formation of reactive AGEs, which are 
thought to be implicated in the formation of micro- and macrovascular complications in 
diabetes mellitus. Proteins such as serum albumin, collagen, elastin, lens crystalline, are 
particularly susceptible to glucose modification (Festa et al., 1998). Elevated serum levels of 
these glycated proteins were detected in diabetic subjects moreover, higher levels of 
glycated form of proteins or AGEs were found in diabetic patients with secondary 
complications such as retinopathy, nephropathy and artherosclerosis (Nicoloff et al., 2000; 
Nicoloff 2001; Ahmed 2005). Previous studies showed reactive AGE can directly alter the 






collagen cross-linking, basement membrane thickening, and covalent trapping of plasma 
proteins such as LDL and IgG (Bouma et al., 2003). Ex vivo HSA was incubated with glucose 
at the concentration of 50 mM for 5 weeks at 37°C under aerobic conditions (Khan et al., 
2007). Biochemical, spectral, electrophoretic, circular dichroism spectropolarimetric, and 
thermodynamic analyses confirmed that the structure and stability of HSA is significantly 
affected by glucose induced modification. Recently we showed that gluco-oxidation of 
proteins alter the structural complexity of the molecule and make them highly immunogenic 
(Khan et al., 2010). Ex vivo designed gluco-oxidative modified human serum albumin (RG-
HSA) were used as an antigen and the titres of antibodies against (RG-HSA-Abs) it were 
screened in both types of diabetic patients, as well as screening was also done in diabetic 
patients with complications like retinopathy, nephropathy and artherosclerosis (Table 1). 
Interestingly, diabetic patients with associated complications (retinopathy, nephropathy and 
atherosclerosis) generated higher autoantibodies against gluco-oxidative modified HSA 
than controls and diabetic subjects without secondary complications. This above contention 
supports that gluco-oxidative proteins are toxic and highly immunogenic. From overall 
cohort of diabetic patients, the highest recognition of RG-HSA as an antigen by circulatory 
autoantibodies from diabetic retinopathy as compared to diabetic nephropathy and 
atherosclerosis (Table 1).  
 








Type 1 diabetes 
(n = 30) 
21 (52 ± 5.5) - 1 (43 ± 4.71; 51 ± 5.22) 2.9 ± 0.35 
Type 2 diabetes 
(n = 30) 
16 (48 ± 4.7) - 2 (47 ± 4.71; 43 ± 5.22, 
45 ± 3.31; 41 ± 4.72) 
2.8 ± 0.4 
Diabetes retinopathy
(n = 12) 
8 (76 ± 4.5) - - 3.9 ± 0.5 
Diabetes 
nephropathy 
(n = 12) 
7 (69 ± 3.1) 1 (41 ± 4.7) - 3.5 ± 0.35 
Diabetes 
atherosclerosis 
(n = 14) 
9 (67 ± 4.0) - 1 (55 ± 4.11; 55 ± 2.82) 3.3 ± 0.55 
Controls NH 
(n = 60) 
- - - 2.3 ± 0.42 
Table 1. Detection of N-HSA-Abs and RG-HSA-Abs and the estimation of carbonyl contents 
as oxidative stress in the sera of various diabetic groups and control. ELISA plate coated 
with the respective antigen (20 µg/ml). Sera positive means serum samples which gave 
inhibition greater than 30%, as less than that may be due to non specific bindings. n denotes 
the number of sera tested. Values in parentheses are mean ± SD of maximum percent 
inhibition of positive serum samples at 20 µg/ml of competitor. 1ROS-glycated and 2native 
HSA were used as inhibitor.   
Diabetic retinopathic patients also exhibited maximum amount of carbonyl content, which 
showed a significant correlation between high oxidative stress and presence of anti-RG-HSA 
antibodies. Clinical and Laboratory examination was also done for 96 diabetic patients (66 
males and 30 females) and 60 normal human (41 males and 19 females) serve as controls. 
According to the data given in Table 2, oxidative stress with chronic hyperglycemia and 
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advanced age has been considered a potential risk factor in the development of 
autoantibodies in retinopathy and other diabetic complications as well. AGEs are products 
of oxidative modifications of glycated proteins, which damage blood proteins. High 
oxidative stress and toxic blood glucose levels are found to be the common factors behind 
the generation of high autoantibodies and the progression of disease complications. 
 












Type 1 diabetic 30 36 ± 14 9 ± 3 254 ± 32 7.4 ± 0.6 
Type 2  diabetic 30 44 ± 11 7 ± 3.6 263 ± 28 7.1 ± 0.4 
Diabetic 
retinopathy 




12 62 ± 4.3 18 ± 3.3 394 ± 13 9.2 ±0.6 
Diabetic 
atherosclerosis 
12 59 ± 3.6 17 ± 3.6 390 ± 15 8.8 ± 0.3 
Control NH 60 32 ± 9.5 ̶ 88 ± 9.8 5.8 ± 0.4 
Table 2. Clinical characterization of the patients and normal control subjects. For the blood 
glucose estimations, blood was collected in oxalated fluoride containers and the assays were 
performed immediately. Values are in mean ± SD. NH represents normal human subjects. 
Gluco-oxidative modified HSA was immunized in the white New-Zealand rabbit that 
exhibited high titre of anti-glycated albumin antibodies in the serum of experimental 
animals (Khan et al., 2010). High titre showed immunogenicity of the gluco-oxidative 
modified proteins. These antibodies were proven to be a potential probe for the detection of 
protein lesion in blood proteins during diabetes mellitus. ELISA experiments of these 
antibodies with the isolated blood proteins such as albumin, IgG and RBC membrane from 
the diabetic patients showed high recognition. It means that during hyperglycemia there is 
damage of blood proteins that modifies the normal conformation of and hence generate 
new-epitopes that share binding specificity with the ex vivo designed gluco-oxidative 
modified albumin. Moreover, anti-gluco-oxidative modified HSA antibodies showed cross 
reaction with proteins such as BSA, poly L-lysine, immunoglobulins that were incubated ex 
vivo with 25 μM of glucose or fructose for 20 days. These findings suggests that paratopes of 
anti-gluco-oxidative albumin antibodies recognise common epitopes that are present in 
most  gluco-oxidative modified proteins.  
During diabetes, persistent hyperglycemia causes increased production of free radicals, 
especially ROS in all tissues by glucose auto-oxidation, protein glycation and due to 
decreased destruction by nonenzymic and enzymic catalase , glutathione peroxidase, and 
superoxide dismutase activity (Kowluru et al., 2001; Baynes & Thorpe 1999; Haskins et al., 
2003). The level of these antioxidant enzymes critically influences the susceptibility of 
various tissues to oxidative stress and is associated with the development of complications 
in diabetes. Also this is particularly relevant and dangerous for the beta islet, which is 
among those tissues that have the lowest levels of intrinsic antioxidant defences (West 2000; 






defence mechanisms may lead to ineffective scavenging of reactive oxygen species, resulting 
in oxidative damage and tissue injury. 
Antibodies against glutamic acid decarboxylase-65 (GAD65Abs) are often considered to be 
an epiphenomenon resulting from the autoimmune destruction of the pancreatic beta cells 
in type 1 diabetes. Previous studies suggest that they are involved in antigen processing and 
presentation and thus modulate the immune response (Banga et al., 2004). Because of the 
high diagnostic sensitivity for autoimmune diabetes, the presence of GAD65Ab is currently 
used to identify subjects at high risk for the disease. GAD65Abs are detected in about 60% of 
new-onset cases of type 1 diabetes, and high levels of these autoantibodies were also 
reported in diabetic patients with secondary complications (such as retinopathy and 
nephropathy), the leading cause of blindness and renal failure (Falorini et al., 1998; Bonifecio 
et al., 1995; Jakuc & Reitbrock 2004). The exact aetiology behind these complications is not 
completely clear. In our recent study; ROS modified GAD65 was found to be more 
immunogenic in T1D than its native form (Khan et al., 2009). GAD65Abs in T1D are 
predominantly directed at conformational epitopes located in the middle region of the 
molecule, whereas they also recognize linear epitopes and epitopes located in the middle, 
COOH- and NH2-terminuses (Hampe et al., 2000). Shifts in GAD65 epitopes were detected 
in a subgroup of newly diagnosed children within the first 12 months after disease onset 
(Hampe et al., 1999). Moreover, epitope spreading has gained credence as a major driver 
underlying autoimmunity (Cheung & Wong 2007). Growing evidence suggests that ROS 
plays an important role in the initiation and progression of diabetes and its associated 
complications. These increased levels of free radicals pose a direct toxic effect on GAD65 
and increase its immunogenicity. Specificity of autoantibodies for epitopes on GAD65 and 
their levels may be a better indicator of impending or actual destruction of islet beta-cells 
and increasing complications associated with diabetes. 
In our 2009 study (Khan et al., 2009), while searching for a potential epitopes, high titre 
autoantibodies were detected in type 1 diabetes patients.  GAD65 was considered a potential 
marker for type 1 diabetes. GAD65 was exposed to hydroxyl radical (ROS-GAD65), induced 
structural and conformational alterations were observed and investigated. Presence of 
autoantibodies against them were found in diabetes patients.  Higher titres of 
autoantibodies were detected against ROS modified GAD65 (ROS-GAD65-Abs) in type 1 
diabetic patients as compared to unmodified native GAD65. Increased levels of ROS in type 
1 diabetes by molecular pathways or over produced metal catalyzed reactions modified 
GAD65 and induced biophysical structural alterations that would probably alter 
immunogenicity leading to induction and elevated levels of autoantibodies in type 1 
diabetes. The data demonstrates possible role of ROS in presenting neo-epitopes that may be 
one of the factors in antigen-driven autoimmune response. Specificity of autoantibodies for 
epitopes on GAD65 and their levels may be a better indicator of impending or actual 
destruction of islet beta-cells and increasing complications associated with diabetes. The 
etiology of ROS-GAD65 in the pathogenesis of diabetic complications was further 
investigated in patients’ diabetic complications in our new study (Khan et al., 2011). In this 
finding, significantly high levels of circulating ROS-GAD65Abs were detected in 
complicated diabetic patients especially in retinopathy as compared to uncomplicated type1 
diabetic patients (Table 3).  
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16(80) 3.9 ± 0.31 
Control (n=50) 32 ± 8 28:22 — — 96 ± 11.2 5.8 ± 
0.4
7.2 ± 3.7 4(8) 2.1 ± 0.17 
Table 3. Clinical and laboratory data from complicated and uncomplicated T1D patients; 
normal human subjects serve as controls. Data are means ± SD. The sign “* “represents 
number of smokers from given total respective subjects. For blood glucose estimations, 
blood was collected in oxalated fluoride containers and the assays were performed 
immediately. Hypertension is defined as sitting systolic blood pressure ≥140mmHg and/or 
diastolic blood pressure ≥90 mmHg or the use of antihypertensive medication. Signs * 
represents 20 number of sera from different patients in the respective group. R-GAD65-Abs 
(Antibodies against ROS modified GAD65). 
This risk of the disease may be enhanced due to acceleration in the formation of free radicals 
with gradual increase in duration of disease. Smoking and hypertension were also 
associated with increased antibody production in diabetic retinopathy. Gluco-oxidative 
stress leads to conformational alterations in native GAD65 protein which could increase or 
expose cryptic epitopes. Dynamic changes in the GAD65Abs binding pattern suggest 
subsequent epitopes spreading with disease progression. Concomitantly, these two studies 
on GAD65 provide us the evidences that hyperglycemia, age, oxidative stress, smoking, and 
as well as extent of blood protein glycation (HbA1C) participate in etiology of increased 
GAD65Ab immunogenicity implicated in diabetic retinopathy. 
The exact mechanism for the formation of these autoantibodies and progression of diabetic 
retinopathy is still not well explained. We hypothesized that anti-gluco-oxidative protein 
autoantibodies bind to soluble glycated proteins and form an intermediary immune 
complex in the bloodstream that can bind to the basement membranes of the retinal blood 
vessels. At these sites they can activate complement cascade, resulting in damage to the 
walls of microvascular cappillaries associated with diabetic retinopathy. This phenomenon 
results in local necrosis of the vessels. If there is no continuous source of antigen, under 
conditions of controlled hyperglycemia then gluco-oxidative modified proteins are cleared 
and the disease can be controlled. However, if there is chronic hyperglycemia that enhances 
a continuing modification of blood protein, formation of increased immune complexes cause 
chronic autoimmune pathogenesis of diabetic retinopathy. 
Gluco-oxidation associated damage of proteins due to hyperglycemia can be enhanced due 






can accelerate production of autoantibodies. This suggests that it is perhaps the rate of 
accumulation rather than the absolute concentration of gluco-oxidative proteins that is 
important. The exact mechanism behind the production of these autoantibodies is yet to be 
elucidated. However it stands to reason that the measurement of serum levels of gluco-
oxidative proteins or anti-gluco-oxidative modified protein antibodies is important for 
estimation of an increased risk for development of diabetic retinopathy. 
7. Conclusion 
Gluco-oxidation is considered to be an important pathophysiological mechanism in the 
development of diabetic retinopathy. Gluco-oxidation leads to toxicity of blood proteins in 
diabetic retinopathic patients. Considerable amounts of AGEs are formed from blood proteins 
that subsequently develop into immune complexes with anti-AGE antibodies in  retinopathic 
subjects. The ROS and gluco-oxidative modified protein autoantibodies were detectable in 
high titers in patients suffering from diabetic retinopathy. Chronic hyperglycemia and 
increased age, that are often seen in such cases, have proven to cause abnormally high 
production of free radicals with decreased antioxidant defence system. Proteins are damaged 
by the concomitant effect of glycation and oxidative stress leading to conformational 
alterations in native structure which could induce neo-epitopes or may increase exposed 
cryptic epitopes. Dynamic changes in the autoantibody binding patterns suggest subsequent 
epitope spreading with disease progression. Immune complexes of gluco-oxidative proteins 
and antibodies against them possibly activate complement cascade system and hence destroy 
capillaries within the retina. Measurement of these autoantibodies could be useful in assisting 
the prediction of the development of disease even before non-proliferative diabetic 
retinopathy. Reduction in the levels of glycation and ROS may lead to decrease in in vivo 
protein modifications, thus delaying the progression of diabetic retinopahy.  
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